Enter the user name below.
A reset password link will be sent to the account's email.
The NeoGenomics website will be going through regularly scheduled maintenance on Thursday, November 20 starting at 6:00 pm PT | 9:00 pm ET. You may experience intermittent downtime of the website for approximately 30 minutes while this work is performed.
If you have any questions, please contact the NeoGenomics Client Services team at clientservices@neogenomics.com or call 866.776.5907, Option 3.
The c-MET CDx for Non-small cell lung cancer (NSCLC) is now available as part of our comprehensive NSCLC testing portfolio and can be added on to PanTracer™ Tissue orders, enabling comprehensive biomarker profiling for lung cancer patients. Learn how c-MET testing can transform your approach to lung cancer care. We invite you to visit us online.
NeoGenomics has partnered with Servier to provide IDHNow for AML, a sponsored testing program for eligible AML patients, through December 31, 2025. Orders received and accessioned between now and December 31 will be processed through the IDHNow for AML sponsored testing program as normal. Upon the program’s conclusion, NeoGenomics will continue to offer testing solutions for AML patients, including IDH1 and IDH2 testing, and support oncologists in making informed treatment decisions. For more information on these solutions, To learn more and order today, please visit our website.
Claudin18 is a new actionable target for patients with advanced or metastatic gastric/GEJ adenocarcinoma who may be eligible for biomarker-driven therapy. NeoGenomics is one of the leading laboratories that offers Claudin18 testing. Biomarker-informed decision-making reveals opportunities to advance care and identify those who may benefit from targeted therapies. Learn how Claudin18.2 testing can transform your approach to gastric cancer care. We invite you to visit us online.
1. Puentes, R. The Importance of Comprehensive Testing in Myeloid Neoplasms: Insights from Real-World Genomics Data. NeoGenomics Laboratories; 2025. Accessed October 10, 2025.
Comprehensive genomic profiling (CGP) plays a pivotal role in differentiating disease subtypes and resolving complex diagnostic challenges associated with MDS and CMML. Neo Comprehensive® – Myeloid Disorders, a guideline-driven CGP assay, uses DNA and RNA next-generation sequencing (NGS) to detect relevant aberrations for diagnostic evaluation, prognosis, risk stratification, and therapy guidance for MDS, CMML, and other myeloid disorders, enhancing clinical decision-making and driving informed care.
Logistics: FedEx is closed on Thursday, November 27th for the US Thanksgiving Day holiday (no pickups or deliveries). Any specimens shipped from client locations on Wednesday, November 26th will have an expected delivery day of Friday, November 28th. Though regularly scheduled daily pick-ups will not occur on Thursday, November 27th, we are available to pick up STAT cases or specimens where viability is a concern. For these cases, please call Client Services at 866.776.5907, option 1 for assistance. Operations: NeoGenomics Operations will continue to process samples on Thanksgiving Day, Thursday, November 27th to deliver quality test results with no delays to turnaround time caused by the holiday. Client Services: Representatives will be available to provide assistance as needed on Thursday, November 27th. Please call 866.776.5907, and press option 3. Billing: Please call 866.776.5907, press option 2, and follow the prompts to leave a message. Your call will be returned on Monday, December 2nd.